Cambrex completes GMP manufacturing expansion in Estonia

The expansion will accelerate the progression and tech transfer of projects within the early clinical development phases

Almost three weeks after announcing expansion plans for cGMP analytical testing capabilities at its Longmont, Colorado facility, Cambrex has completed an upgrade project at its Tallinn, Estonia site.

Having upgraded its kilogram-scale laboratory, the CDMO can now manufacture pharmaceutical intermediates under current good manufacturing practice (cGMP) conditions.

Part of the investment project has seen the company install a new 160-L reactor train in the laboratory to expand the site’s capabilities to manufacture material for clinical trials. The company will also be able to further develop early-phase projects at the site prior to tech transfer and scale up.

The facility also houses 150-L glass and stainless-steel reactors, which will continue to offer kilogram-scale manufacturing of materials for pre-clinical toxicological study applications.

The Tallinn site is adjacent to Tallinn University of Technology’s campus, allowing for strong collaboration with the University’s analytical and chemistry departments.

According to Joe Nettleton, President of Cambrex’s Drug Substance Business Unit, the Cambrex teams at Tallinn and the manufacturing site at Karlskoga, Sweden work closely together. This intersite co-operation coupled with the expansion will "accelerate the progression and tech transfer of projects within the early clinical development phases".

Now that construction work is complete and the new reactor and supporting equipment have been installed, Cambrex is currently preparing for GMP qualification.